The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
about
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapiesPatient considerations in type 2 diabetes - role of combination dapagliflozin-metformin XRSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewThe altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic micePharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus.Dapagliflozin efficacy and safety: a perspective review.DapagliflozinExposure-response modelling for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes.Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetesDapagliflozin for the treatment of type 2 diabetes: a review of the literatureSodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agentsDapagliflozin in patients with type 2 diabetes mellitus.Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes MellitusA Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment.Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearanceSGLT-2 inhibitors and their potential in the treatment of diabetes.Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations.Anti-diabetes therapy: safety considerations for patients with impaired kidney function.Dapagliflozin: drug profile and its role in individualized treatment.Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Novel avenues for treating diabetic nephropathy: new investigational drugs.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis.Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies.Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model.Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.Effects of renal impairment on transporter-mediated renal reabsorption of drugs and renal drug-drug interactions: A simulation-based study.
P2860
Q26744317-EE5508E1-B561-488D-88AA-02C98C3E646AQ26766404-B66839E6-0F36-4D61-B59B-AEFF5073D1DCQ28079134-B8838DDD-6B38-476D-A636-E66A4B2DB390Q28544698-88032078-B16A-4AC2-BE58-ACB98A6884B8Q34208581-8E17075B-13A9-4ED7-A84C-0EBE9E4ED155Q34397646-DFE91027-7358-4E88-A38D-DBCC728ADF3BQ34514280-928725DB-82AD-4710-9D43-C70805921D48Q34613015-4BA835D1-10BE-4B74-94B3-184825103847Q34635575-836C0896-055A-4751-B4B9-C57FC873983AQ34699217-78B2687D-D57E-4ECB-9174-AAF7F5D56AA6Q34710819-3B515E88-24FB-4BDA-9F2D-9FF043726405Q34973750-A8712155-45A8-4AA2-8B22-D4CED5A34D38Q35064363-55D02F03-DFA4-4FAC-8194-444B58F538B0Q36798684-12861BE5-7445-46EA-9A9B-3063F5AE99BEQ36804248-FC083DC6-6186-45F7-AD17-1300F0427CBAQ36907014-6F3135A5-3064-4E9C-8831-FF93F430D22BQ36924729-C01D3922-EBB4-4365-AF00-776CDAD9FD87Q37359631-9B3BD3B3-8851-4168-82E7-EBE06C755304Q37679893-401A836C-3E89-418D-BEC5-3B7756C92450Q38175467-46D5841F-C23C-4EA3-A0CA-47F1DC81FA61Q38219489-8482302C-A5FF-49AD-930E-0863594009D1Q38308333-90893AD7-38AE-4BF8-9D13-4AAA0808EC76Q38311095-2D785257-AFB2-4455-99F8-F6D9F8724E0DQ38389823-EE5CEB8D-4420-459F-90FE-35E3CF90BE34Q38619164-E4887B8B-8C08-455D-8565-82614B482A4DQ38908779-937EFF1A-0F5C-458A-BEAF-AF77BBB84DC1Q39170387-47406904-E7A6-4AA8-B60D-C4B2DD3325DEQ39290337-EE22DCB8-A85F-42BD-8AE2-1BCCCB28176EQ39325947-70797B32-2FB0-4377-98F5-88E7728E8207Q39684916-55C5541C-E9C1-4725-968B-BE1EB8C5BA12Q40382882-B8479BC8-A727-4D13-9F11-ED44C84CBA6CQ41168197-A909BFFE-8882-4C4F-870E-DB9EDA52CF39Q41922447-27E154E7-B8B6-42CE-9952-F8D56DC7BE3FQ51321207-1C86A888-6036-4DCD-A7A3-462F5CE515CAQ52595858-23B1E072-C39C-46AF-85A3-FF4CD8E667D8
P2860
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The influence of kidney functi ...... with type 2 diabetes mellitus.
@ast
The influence of kidney functi ...... with type 2 diabetes mellitus.
@en
The influence of kidney functi ...... with type 2 diabetes mellitus.
@nl
type
label
The influence of kidney functi ...... with type 2 diabetes mellitus.
@ast
The influence of kidney functi ...... with type 2 diabetes mellitus.
@en
The influence of kidney functi ...... with type 2 diabetes mellitus.
@nl
prefLabel
The influence of kidney functi ...... with type 2 diabetes mellitus.
@ast
The influence of kidney functi ...... with type 2 diabetes mellitus.
@en
The influence of kidney functi ...... with type 2 diabetes mellitus.
@nl
P2093
P2860
P356
P1476
The influence of kidney functi ...... with type 2 diabetes mellitus.
@en
P2093
David W Boulton
Frank P LaCreta
Marc Pfister
Melanie Pe Benito
Sreeneeranj Kasichayanula
William Griffith Humphreys
Xiaoni Liu
P2860
P304
P356
10.1111/BCP.12056
P407
P577
2013-09-01T00:00:00Z